AU2003253128B2 - Modafinil polymorphic forms - Google Patents

Modafinil polymorphic forms Download PDF

Info

Publication number
AU2003253128B2
AU2003253128B2 AU2003253128A AU2003253128A AU2003253128B2 AU 2003253128 B2 AU2003253128 B2 AU 2003253128B2 AU 2003253128 A AU2003253128 A AU 2003253128A AU 2003253128 A AU2003253128 A AU 2003253128A AU 2003253128 B2 AU2003253128 B2 AU 2003253128B2
Authority
AU
Australia
Prior art keywords
modafinil
crl
solvate
powder
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003253128A
Other languages
English (en)
Other versions
AU2003253128A1 (en
Inventor
Michel Broquaire
Gerard Coquerel
Laurent Courvoisier
Armand Frydman
Franck Mallet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Sante SAS
Original Assignee
Teva Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Sante SAS filed Critical Teva Sante SAS
Publication of AU2003253128A1 publication Critical patent/AU2003253128A1/en
Assigned to CEPHALON FRANCE reassignment CEPHALON FRANCE Request for Assignment Assignors: CEPHALON FRANCE, ORGANISATION DE SYNTHESE MONDIALE ORSYMONDE
Application granted granted Critical
Publication of AU2003253128B2 publication Critical patent/AU2003253128B2/en
Assigned to TEVA SANTE reassignment TEVA SANTE Request to Amend Deed and Register Assignors: CEPHALON FRANCE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2003253128A 2002-08-09 2003-08-08 Modafinil polymorphic forms Ceased AU2003253128B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40206402P 2002-08-09 2002-08-09
US60/402,064 2002-08-09
US10/635,445 US6992219B2 (en) 2002-08-09 2003-08-07 Modafinil polymorphic forms
US10/635,445 2003-08-07
PCT/IB2003/003215 WO2004014846A1 (en) 2002-08-09 2003-08-08 Modafinil polymorphic forms

Publications (2)

Publication Number Publication Date
AU2003253128A1 AU2003253128A1 (en) 2004-02-25
AU2003253128B2 true AU2003253128B2 (en) 2009-01-29

Family

ID=31720568

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003253128A Ceased AU2003253128B2 (en) 2002-08-09 2003-08-08 Modafinil polymorphic forms

Country Status (11)

Country Link
US (3) US6992219B2 (enExample)
EP (2) EP1575915A1 (enExample)
JP (2) JP4718177B2 (enExample)
CN (3) CN102875429B (enExample)
AU (1) AU2003253128B2 (enExample)
CA (4) CA2804385A1 (enExample)
IL (3) IL166301A (enExample)
MX (1) MXPA05001506A (enExample)
NZ (1) NZ537840A (enExample)
WO (1) WO2004014846A1 (enExample)
ZA (1) ZA200500411B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000747A (es) 2000-07-27 2003-06-04 Teva Pharma Modafinilo cristalino y puro y proceso para prepararlo.
ATE374028T1 (de) * 2001-03-27 2007-10-15 Dainippon Sumitomo Pharma Co Kristallines isoxazol-derivat und medizinisches präparat daraus
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
WO2004075841A2 (en) * 2003-02-24 2004-09-10 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
WO2004083183A1 (en) * 2003-03-21 2004-09-30 Hetero Drugs Limited Novel crystalline forms of aripiprazole
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
WO2004085426A1 (en) * 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
WO2004087660A1 (en) * 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US7560560B2 (en) * 2003-04-16 2009-07-14 Hetero Drugs Limited Crystalline forms of donepezil hydrochloride
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2330321T3 (es) 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
ES2803516T3 (es) 2003-10-16 2021-01-27 Symed Labs Ltd Una forma cristalina de linezolid
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
ES2294494T3 (es) * 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
ATE483455T1 (de) 2004-05-28 2010-10-15 Transform Pharmaceuticals Inc Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
CA2754932C (en) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE
US7518019B2 (en) * 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
JP2009543803A (ja) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド モダフィニルのナノ粒子製剤
DK2056811T3 (en) * 2006-08-14 2018-05-22 Neurohealing Pharmaceuticals Inc Modafinil-based treatment for premature ejaculation
EP2083628A1 (en) 2006-11-10 2009-08-05 Basf Se Crystalline modification of fipronil
UA110598C2 (uk) 2006-11-10 2016-01-25 Басф Се Спосіб одержання кристалічної модифікації фіпронілу
HRP20110641T4 (hr) 2006-11-10 2015-05-22 Basf Se Kristalna modifikacija fipronila
US20100093804A1 (en) * 2006-12-07 2010-04-15 Hetero Drugs Limited novel crystalline form of lansoprazole
CN101641090B (zh) * 2006-12-19 2012-12-05 亚勒斯有限公司 莫达非尼在制备治疗多动腿综合征的药物中的应用
CA2688430A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2015086489A1 (en) 2013-12-11 2015-06-18 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
ES3060948T3 (en) 2020-09-14 2026-03-30 Pharma Cinq Llc 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
DK4255563T3 (da) 2020-12-01 2026-03-16 Pharma Cinq Llc 5´-o-phenylacetyluridin og terapeutisk anvendelse
EP4294405A4 (en) 2021-02-21 2025-01-29 Pharma Cinq, LLC COMPOSITIONS AND COMPOUNDS FOR CO-ADMINISTRATION OF URIDINE AND KETOLEUCINE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives
WO2002010125A1 (en) * 2000-07-27 2002-02-07 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520812A (en) * 1975-10-02 1978-08-09 Lafon Labor Benzhydrylsulphinyl derivatives
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2706767B1 (enExample) 1993-06-22 1995-09-08 Lafon Labor
FR2707637B1 (fr) * 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) * 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IL128989A0 (en) 1999-03-15 2000-02-17 Popov Sergey Safety trocar assembly
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
AR045314A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Composiciones farmaceuticas de analepticos y antidepresivos
US20040242698A1 (en) * 2003-05-13 2004-12-02 Cephalon Inc. Analeptic and antidepressant combinations
US20040229941A1 (en) * 2003-05-13 2004-11-18 Cephalon, Inc. Analeptic and antidepressant combinations
AR045423A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
ES2330321T3 (es) 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.
US20040229943A1 (en) * 2003-05-16 2004-11-18 Cephalon Inc Analeptic and drug combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives
WO2002010125A1 (en) * 2000-07-27 2002-02-07 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same

Also Published As

Publication number Publication date
CA2746788C (en) 2013-04-09
JP2011046730A (ja) 2011-03-10
US20060252835A1 (en) 2006-11-09
IL209966A (en) 2013-02-28
JP2005535698A (ja) 2005-11-24
US20080153918A1 (en) 2008-06-26
EP1575915A1 (en) 2005-09-21
CA2494010A1 (en) 2004-02-19
CA2494010C (en) 2011-10-18
CA2840721A1 (en) 2004-02-19
IL209965A0 (en) 2011-07-31
JP4718177B2 (ja) 2011-07-06
MXPA05001506A (es) 2005-08-16
US6992219B2 (en) 2006-01-31
WO2004014846A1 (en) 2004-02-19
CN1675177A (zh) 2005-09-28
ZA200500411B (en) 2006-07-26
US7405323B2 (en) 2008-07-29
IL209966A0 (en) 2011-07-31
CA2746788A1 (en) 2004-02-19
IL166301A (en) 2011-06-30
CN102875430A (zh) 2013-01-16
NZ537840A (en) 2007-01-26
AU2003253128A1 (en) 2004-02-25
IL166301A0 (en) 2006-01-15
CN100506790C (zh) 2009-07-01
JP5307106B2 (ja) 2013-10-02
CA2804385A1 (en) 2004-02-19
EP2402311A1 (en) 2012-01-04
US20040102523A1 (en) 2004-05-27
CN102875429B (zh) 2014-12-10
US7649020B2 (en) 2010-01-19
CN102875429A (zh) 2013-01-16
CA2840721C (en) 2015-06-16

Similar Documents

Publication Publication Date Title
CA2746788C (en) Modafinil polymorphic forms
TWI344952B (en) Process for the preparation of and crystalline forms of optical enantiomers of modafinil
JP2005535698A5 (enExample)
CN1812968B (zh) 4-[6-乙酰基-3-[3-(4-乙酰基-3-羟基-2-丙基苯硫基)丙基]-2-丙基苯氧基]丁酸的多晶型物
CN119462561A (zh) 化合物的晶型及其制备方法、原料药、组合物和用途
JP2001521023A (ja) ドフェチリド多形
JP7835785B2 (ja) シクロヘキセノン化合物の結晶形
CN112047990B (zh) 阿糖胞苷前药mb07133晶型及其应用
CN101619033B (zh) 莫达非尼多晶型
JP2026500850A (ja) ペオニフロリン一水和物の結晶型ａおよびその調製方法と使用
HK1192221A (en) Preparation methods of crystalline forms of optical enantiomers of modafinil and pharmaceutical composition thereof
HK1192220A (en) Preparation methods of forms of optical enantiomers of modafinil and pharmaceutical composition thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CEPHALON FRANCE

Free format text: FORMER APPLICANT(S): CEPHALON FRANCE; ORGANISATION DE SYNTHESE MONDIALE ORSYMONDE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired